Clinical Trial

CAtheter-Based Ablation of Atrial Fibrillation Compared to Conventional Treatment in Patients With Heart Failure With Preserved Ejection Fraction

Study acronym: CABA-HFPEF
Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated March 6, 2023 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The objective of CABA-HFPEF is to test whether catheter ablation (CA) for atrial fibrillation (AF) can prevent adverse cardiovascular outcomes in patients with heart failure with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-08-17.
Status change: Not Yet Recruiting → Recruiting 2023-03-03
Trial Details
NCT Number NCT05508256
Lead Sponsor Charite University, Berlin, Germany
Collaborators: Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Kompetenznetz Vorhofflimmern e.V. (AFNET), Boston Scientific Corporation
Conditions Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Enrollment 1,548 participants
Start Date 2023-03
Primary Completion 2026-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2023-03-06